Medtronic to acquire Contego Medical in $380 million deal
The carotid therapy maker brings the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices to Medtronic.
Key takeaways
- Medtronic plans to acquire Contego Medical in a deal valued at $380 million with potential payments post-acquisition.
- Medtronic expects the deal to be minimally dilutive to adjusted EPS in FY27 and FY28 and neutral to accretive thereafter.
- The deal includes the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.
Medtronic announced on Nov. 16, 2026 its intent to acquire Contego Medical, a privately held medical device company, in a Medtronic deal valued at $380 million with potential payments post-acquisition. Contego focuses on carotid artery disease and peripheral thrombectomy.
According to the release, the acquisition builds on an exclusive US distribution agreement with Contego, first announced in January 2025. It advances the Medtronic strategy of targeted investments that strengthen its core franchises.
Medtronic deal: the details
| Consideration (cash / stock / assumed debt) | Valued at $380 million with potential payments post-acquisition |
|---|---|
| What is acquired or divested | Contego Medical, including the Neuroguard IEP Direct System and Excipio thrombectomy devices |
| Guidance after close | Minimally dilutive to Medtronic adjusted EPS in FY27 and FY28 and neutral to accretive thereafter |
| Closing conditions and timing | Third quarter of Medtronic’s fiscal year, subject to customary closing conditions |
- “With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health.
- “Deepening our partnership with Medtronic is an exciting next chapter,” said Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical.
- “Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease,” said Linnea Burman, senior vice president and president of Medtronic Neurovascular.
The planned acquisition includes the recently FDA-approved Neuroguard IEP Direct System, Medtronic said. The company called it the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the prospective, multicenter PERFORMANCE III study, the system showed zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days.
The deal also includes Contego’s Excipio thrombectomy devices, according to the release. They complement Medtronic’s Liberant thrombectomy system in treating peripheral vascular disease.
Carotid artery disease occurs when the carotid arteries, which supply the brain, become narrowed or blocked, the release said. Plaque can rupture or embolize and lead to a stroke, accounting for about 20% of ischemic strokes. Embolic debris released during carotid revascularization can contribute to procedural stroke risk.
Background to the Medtronic deal
Medtronic plc is a healthcare technology company headquartered in Galway, Ireland, according to the release. It has a team of 90,000+ people across more than 150 countries. Its technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools and patient monitoring systems. Contego Medical’s investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.
The news moving money, markets, and the world—before your day starts.
Daily. Free. Join 34,000+ readers across crypto, finance, and policy.
What this means
Medtronic said the deal turns an existing distribution partnership into ownership of Contego’s carotid and thrombectomy lines. The transaction still awaits customary closing conditions, and the potential payments post-acquisition remain part of its value.
Analysis
The acquisition converts a distribution relationship, first announced in January 2025, into full ownership, which could give Medtronic more control over Contego’s carotid technology. The PERFORMANCE III results at 30 days likely underpin the company’s aim to lead in carotid revascularization.
For MDT holders, the financial effect appears modest: Medtronic projects minimal adjusted EPS dilution in FY27 and FY28, then neutral to accretive results. Open points include the size and conditions of potential payments post-acquisition and completion of customary closing conditions.
What to watch
- 2026-11-24: MDT reports quarterly results. Management may update investors on the Contego acquisition and its expected EPS effect.
- third quarter of its fiscal year: Expected closing of the Contego Medical acquisition. Closing depends on customary conditions and brings Contego’s devices into Medtronic.
- Potential payments post-acquisition. These payments form part of the deal’s stated value.
The crypto angle
- Medtronic Plc has 4 tokenized versions across 5 known blockchains: Arbitrum One, BNB Smart Chain, Ethereum, Solana, and Morph.
More market coverage: Crypto Briefing Markets
Source: Medtronic, 2026-11-16 11:45 UTC
Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.

